Drugs / FLX925
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02335814 | Apr 2015 → May 2017 | acute myeloid leukemia | RAPT Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FLX925 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02335814 ↗ |